Immune repertoire refers to sub-type protein that an organism’s immune system creates. Immune systems in vertebrates have six key types of proteins- two immunoglobulin and four T cell receptors. Immune repertoire sequencing enables researchers and scientists to examine and understand adaptive immune-mediated diseases. Immune repertoire sequencing is also widely applicable in biomarker discovery, infectious disease research, asthma and allergy research, and cancer immunotherapy.
Market Dynamics
Increasing prevalence of cancer worldwide is expected to boost immune repertoire sequencing market growth. According to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. Moreover, the number of people suffering from cancer is expected to reach to 19 million by 2024. According to the Cancer Atlas, 2012, about 1.1 million new cancer cases and 600,000 cancer deaths are reported annually in Latin America and the Caribbean, where lung cancer is the leading cause of cancer death for both sexes.
However, factors such as high cost associated with certain sequencing platforms and data analytic services coupled with product recalls are expected to hinder growth of the immune repertoire sequencing market during the forecast period. For instance, in 2015, Illumina Inc. recalled its Illumina MiSeqDx Universal Kit 1.0, due to software limitation when using the product on MiSeqDx instrument. The software could not report insertions or deletions at specific genomic locations with respect to the primer.
Key features of the study:
- This report provides in-depth analysis of the immune repertoire sequencing market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global immune repertoire sequencing market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global immune repertoire sequencing market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for immune repertoire sequencing market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Immune Repertoire Sequencing Market, By Product Type:
- Assay Kits
- T-Cell Receptor (TCR) Kits
- B-Cell Receptor (BCR) Kits
- Instruments
- Global Immune Repertoire Sequencing Market, By Application:
- Cancer Immunotherapy
- Biomarker Discovery
- Autoimmune Diseases
- Vaccine Development and Efficacy
- Transplant Rejection and Tolerance
- Infectious Diseases
- Other Applications
- Global Immune Repertoire Sequencing Market, By End User:
- Diagnostic Labs
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Others
- Global Immune Repertoire Sequencing Market, By Region:
- North America
- By Country:
- By Product Type:
- Assay Kits
- T-Cell Receptor (TCR) Kits
- B-Cell Receptor (BCR) Kits
- Instruments
- By Application:
- Cancer Immunotherapy
- Biomarker Discovery
- Autoimmune Diseases
- Vaccine Development and Efficacy
- Transplant Rejection and Tolerance
- Infectious Diseases
- Other Applications
- By End User:
- Diagnostic Labs
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Product Type:
- Assay Kits
- T-Cell Receptor (TCR) Kits
- B-Cell Receptor (BCR) Kits
- Instruments
- By Application:
- Cancer Immunotherapy
- Biomarker Discovery
- Autoimmune Diseases
- Vaccine Development and Efficacy
- Transplant Rejection and Tolerance
- Infectious Diseases
- Other Applications
- By End User:
- Diagnostic Labs
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Product Type:
- Assay Kits
- T-Cell Receptor (TCR) Kits
- B-Cell Receptor (BCR) Kits
- Instruments
- By Application:
- Cancer Immunotherapy
- Biomarker Discovery
- Autoimmune Diseases
- Vaccine Development and Efficacy
- Transplant Rejection and Tolerance
- Infectious Diseases
- Other Applications
- By End User:
- Diagnostic Labs
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Assay Kits
- T-Cell Receptor (TCR) Kits
- B-Cell Receptor (BCR) Kits
- Instruments
- By Application:
- Cancer Immunotherapy
- Biomarker Discovery
- Autoimmune Diseases
- Vaccine Development and Efficacy
- Transplant Rejection and Tolerance
- Infectious Diseases
- Other Applications
- By End User:
- Diagnostic Labs
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Assay Kits
- T-Cell Receptor (TCR) Kits
- B-Cell Receptor (BCR) Kits
- Instruments
- By Application:
- Cancer Immunotherapy
- Biomarker Discovery
- Autoimmune Diseases
- Vaccine Development and Efficacy
- Transplant Rejection and Tolerance
- Infectious Diseases
- Other Applications
- By End User:
- Diagnostic Labs
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- Assay Kits
- T-Cell Receptor (TCR) Kits
- B-Cell Receptor (BCR) Kits
- Instruments
- By Application:
- Cancer Immunotherapy
- Biomarker Discovery
- Autoimmune Diseases
- Vaccine Development and Efficacy
- Transplant Rejection and Tolerance
- Infectious Diseases
- Other Applications
- By End User:
- Diagnostic Labs
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Company Profiles
- Thermo Fisher Scientific, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Illumina Inc.
- ArcherDX, Inc
- Roche Holding AG
- Pacific Biosciences
- CD Genomics
- Atreca, Inc.
- Adaptive Biotechnologies
- Oxford Nanopore Technologies, Ltd.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Takara Bio, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
